

**Notice Regarding Adjustment of 340B Prices for VELCADE® (bortezomib) for Injection  
(NDC63020-0049-01)**

Millennium Pharmaceuticals, Inc. (“Millennium”) has recalculated its 340B ceiling prices for certain products for the period from Q1-2011 through Q2-2011 (the “Restatement Period”). The products impacted are below. The recalculation of ceiling prices is due to revisions to the Medicaid pricing data for the products listed for the period from Q1-2011 through Q2-2011.

Millennium has determined the credit amount owed to each affected covered entity. Millennium will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each covered entity. Once validated, Apexus will work with the wholesalers to facilitate the processing of credit for the overpayments that the covered entity was charged during the specified periods. If no active wholesaler account can be found, Apexus will work to issue a check to those entities.

<u>NDC</u>	<u>Product Description</u>
63020-0049-01	VELCADE® (bortezomib) for Injection

If any 340B Covered Entity that purchased VELCADE® during an impacted quarter, as identified above, believes it may be eligible for a refund, or has questions regarding the refund process, please send an email to Millennium at [Anne.Emrick@takeda.com](mailto:Anne.Emrick@takeda.com) or submit inquiries via mail, no later than March 31, 2017, to: Millennium Pharmaceuticals, 40 Landsdowne Street, Cambridge, MA 02139 Attn: Anne Emrick.